Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of CC-97540 in AQP4+ NMOSD
NCT07573332Phase 1Not yet recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Sep 2026
- Primary completion
- Aug 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-986353 in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by UT Southwestern Medical Center. Primary endpoints: Dose-Limiting Toxicities at 52 weeks and Sero-reversion Rate at 6 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
BMS-986353
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT07573332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07573332.